Lauren Wardle is an associate in the technology transactions practice at Wilson Sonsini Goodrich & Rosati’s San Diego office. Her practice focuses on the life sciences and medical device industry, representing companies in various intellectual property and commercial transactions. Lauren has also represented life science, medical device, and high-tech companies in complex commercial licensing and patent infringement disputes, including Hatch-Waxman litigation.
During law school, Lauren was a judicial extern for The Honorable Margaret Mann in the United States Bankruptcy Court for the Southern District of California and The Honorable Marilyn L. Huff in the United States District Court for the Southern District of California.
Before attending law school, Lauren worked at a biotechnology company focusing on the development of monoclonal and polyclonal antibodies.
Lauren Wardle is an associate in the technology transactions practice at Wilson Sonsini Goodrich & Rosati’s San Diego office. Her practice focuses on the life sciences and medical device industry, representing companies in various intellectual property and commercial transactions. Lauren has also represented life science, medical device, and high-tech companies in complex commercial licensing and patent infringement disputes, including Hatch-Waxman litigation.
During law school, Lauren was a judicial extern for The Honorable Margaret Mann in the United States Bankruptcy Court for the Southern District of California and The Honorable Marilyn L. Huff in the United States District Court for the Southern District of California.
Before attending law school, Lauren worked at a biotechnology company focusing on the development of monoclonal and polyclonal antibodies.
- J.D., University of San Diego School of Law
- B.A., Molecular and Cell Biology, University of California, Berkeley
- State Bar of California
- J.D., University of San Diego School of Law
- B.A., Molecular and Cell Biology, University of California, Berkeley
- State Bar of California
Traditional TCEs targeting “cold” tumors have limited efficacy due to poor T cell quality and exhaustion. Marengo’s proprietary first-in-class TriSTAR TCEs have the potential to overcome these limitations, redirecting a new and expanded pool of highly activated memory Vβ T cells to the tumor. The teams will focus on exploring potential in cold tumors, which typically fail to trigger a strong immune response when treated with TCEs.
Under the terms of the agreement, Ipsen will assume responsibility for all activities following development candidate nomination. Marengo will receive an upfront payment and potential payments up to a total of $1.2 billion if all milestones are met, in addition to tiered sales royalty payments.
The Wilson Sonsini team advising Marengo Therapeutics on the transaction included Mark Bellomy, Chris McAndrew, Lauren Wardle, and Angel Wang.
- Privacy Policy
- Terms of Use
- Accessibility